GGrantIndex
← Leaderboards

Ahmed A Tawakol

Massachusetts General Hospital

Google Scholar ↗PubMed ↗ORCID ↗
$9,912,063
Attributed
$20,647,441
Total exposure
11
Grants
2
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.6M · FY2005–25
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$20,647,441 · 11

By mechanism

R01$15,786,180 · 6
R33$2,880,523 · 1
R61$729,903 · 1
K23$649,755 · 1
R56$554,780 · 1
F32$46,300 · 1

Top collaborators

Most similar at Massachusetts General Hospital

Same institution · by research overlap

Others in their field

Top investigators on “Cardiovascular Disorder Risk”

Research focus

Cardiovascular Disorder RiskInflammatoryInflammationAtherosclerosisBiological MarkersPet/Ct ScanClinical TrialsFutureHiv InfectionsCollaborationsEventImmune ActivationPlacebosRandomizedChronicBlood VesselsGeneral PopulationFluorodeoxyglucose Positron Emission TomographyAntiretroviral TherapyMediatingPersonsT-LymphocyteMonocyteCardiovascular Diseases

Grant awards (39)

Cholesterol and inflammation Lowering via BEmpedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)$557,915
R01 · FY2025 · HL
Neuroimaging Measures of Psychosocial Stress as Predictors of Articular and Arterial Inflammation and Treatment Response in Rheumatoid Arthritis$447,731
R01 · FY2025 · AR
Reducing Arterial Inflammation and Improving Metabolic Health by Dual CCR2 and CCR5 Antagonism in People Living with HIV$744,797
R01 · FY2024 · HL
Cholesterol and inflammation Lowering via BEmpedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)$596,450
R01 · FY2024 · HL
Impact of Treating Asymptomatic CMV Replication on Cardiovascular Risk in Treated HIV Infection$765,877
R01 · FY2023 · HL
Reducing Arterial Inflammation and Improving Metabolic Health by Dual CCR2 and CCR5 Antagonism in People Living with HIV$750,673
R01 · FY2023 · HL
Cholesterol and inflammation Lowering via BEmpedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)$651,143
R01 · FY2023 · HL
Neuroimaging Measures of Psychosocial Stress as Predictors of Articular and Arterial Inflammation, Cardiometabolic Disease, and Treatment Response in Rheumatoid Arthritis$505,842
R01 · FY2023 · AR
Impact of Treating Asymptomatic CMV Replication on Cardiovascular Risk in Treated HIV Infection$93,412
R01 · FY2023 · HL
Impact of Treating Asymptomatic CMV Replication on Cardiovascular Risk in Treated HIV Infection$78,069
R01 · FY2023 · HL
Reducing Arterial Inflammation and Improving Metabolic Health by Dual CCR2 and CCR5 Antagonism in People Living with HIV$771,996
R01 · FY2022 · HL
Impact of Treating Asymptomatic CMV Replication on Cardiovascular Risk in Treated HIV Infection$726,136
R01 · FY2022 · HL
Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)$721,297
R33 · FY2022 · HL
Cholesterol and inflammation Lowering via BEmpedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)$698,084
R01 · FY2022 · HL
Neuroimaging Measures of Psychosocial Stress as Predictors of Articular and Arterial Inflammation, Cardiometabolic Disease, and Treatment Response in Rheumatoid Arthritis$335,940
R01 · FY2022 · AR
Reducing Arterial Inflammation and Improving Metabolic Health by Dual CCR2 and CCR5 Antagonism in People Living with HIV$778,106
R01 · FY2021 · HL
Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)$721,297
R33 · FY2021 · HL
Impact of Treating Asymptomatic CMV Replication on Cardiovascular Risk in Treated HIV Infection$668,476
R01 · FY2021 · HL
Neuroimaging Measures of Psychosocial Stress as Predictors of Articular and Arterial Inflammation, Cardiometabolic Disease, and Treatment Response in Rheumatoid Arthritis$554,962
R01 · FY2021 · AR
Reducing Arterial Inflammation and Improving Metabolic Health by Dual CCR2 and CCR5 Antagonism in People Living with HIV$829,709
R01 · FY2020 · HL
Novel PET/CT and Treatment Strategies to reduce PTS following DVT$823,128
R01 · FY2020 · HL
Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)$721,297
R33 · FY2020 · HL
Impact of Treating Asymptomatic CMV Replication on Cardiovascular Risk in Treated HIV Infection$675,844
R01 · FY2020 · HL
Neuroimaging Measures of Psychological Distress as Predictors of Articular and Arterial Inflammation and Treatment Response in Rheumatoid Arthritis$554,780
R56 · FY2020 · AR
Novel PET/CT and Treatment Strategies to reduce PTS following DVT$820,597
R01 · FY2019 · HL
Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)$716,632
R33 · FY2019 · HL
Novel PET/CT and Treatment Strategies to reduce PTS following DVT$826,096
R01 · FY2018 · HL
Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)$729,903
R61 · FY2018 · HL
Novel PET/CT and Treatment Strategies to reduce PTS following DVT$845,084
R01 · FY2017 · HL
Effect of Low Dose Methotrexate on Arterial Inflammation in HIV$306,012
R01 · FY2017 · HL · contact PI
Effect of Low Dose Methotrexate on Arterial Inflammation in HIV$44,483
R01 · FY2016 · HL · contact PI
Effect of Low Dose Methotrexate on Arterial Inflammation in HIV$438,305
R01 · FY2015 · HL · contact PI
Effect of Low Dose Methotrexate on Arterial Inflammation in HIV$451,313
R01 · FY2014 · HL · contact PI
LOWERING HOMOCYSTEINE TO REDUCE MYOCARDIAL ISCHEMIA$129,951
K23 · FY2006 · RR · contact PI
LOWERING HOMOCYSTEINE TO REDUCE MYOCARDIAL ISCHEMIA$129,951
K23 · FY2005 · RR
LOWERING HOMOCYSTEINE TO REDUCE MYOCARDIAL ISCHEMIA$129,951
K23 · FY2004 · RR
LOWERING HOMOCYSTEINE TO REDUCE MYOCARDIAL ISCHEMIA$129,951
K23 · FY2003 · RR
LOWERING HOMOCYSTEINE TO REDUCE MYOCARDIAL ISCHEMIA$129,951
K23 · FY2002 · RR
HOMOCYSTEINE AND HUMAN ENDOTHELIAL FUNCTION$46,300
F32 · FY2000 · HL